Oncology Highlights – 30/07/2018
Oncology Highlights – 30/07/2018
Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, a...
Samsung Partnered with Lunit; Boston Scientific Launched VersaVue...
Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple...
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receiv...

Search by Categories

Home / Blog / Notizia / 15

Notizia - Recent Pharma, Healthcare and Biotech Happenings

BioGX’s ‘pixl’ Portable qPCR Platform; Stryker’...

BioGX Announced Ex-US Commercial Launch of ‘pixl™’ Portable qPCR Platform On December 8, 2022, BioGX, a global provider of easy molecular diagnostic solutions, announced the Ex-US commercial...

Dec 15, 2022

MedTech News for BioGX, Stryker, Boston Scientific, Agilent, DexCom
Delveinsight
Amgen to Purchase Horizon Therapeutics; IND Clearance to Vertex’s VX-522; FDA Fast-Track Designation for Moleculin’s WP1122; Orphan Drug Designation to Brim’s WP1122; Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study; UCB Announces Phase 3 Studies for Bimekizumab

Amgen Inc. Agrees to Purchase Dublin-based Horizon Therapeutics Plc. for €24.7 Billion  Amgen Inc. has agreed to buy Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26 billion), in a deal that could face further delays or a breakdown in negotiations. Following Sanofi's withdrawal from the race, c...

Find More
MedTech News and Updates for Olympus, GE, Journey Biosciences, NeuroOne, Enovis
Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System On November 30, 2022, Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, launched the moresolution™ Power Morcellator, manufactured by TROKAM...

Find More
Pharma News for Nkarta, Eisai, EQRx, Rigel Pharma, AUM, X4 Pharma
Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug

FDA Grants Orphan Drug Designation to AUM302 for Neuroblastoma A global clinical-stage biotech company, AUM Biosciences, focused on discovering and developing precision oncology therapeutics, declared that the U.S. FDA has permitted Orphan Drug Designation for AUM302. For the treatment of neuroblastoma, AUM302 i...

Find More

More Views & Analysis

Delveinsight
C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum’s Poziotinib; Orphan Drug Designation to Tenaya’s Gene Therapy; EC Approves Regeneron’s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...

Find More
MedTech News for Empatica, ClariPi, Sony, Mainstay Medical, Zimmer
Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis

Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study  On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...

Find More
Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...

Find More
MedTech News for Medtronic, Penumbra, and Genesis
Medtronic Launches Infusion Set for Insulin Pumps; Penumbra’s Virtual Reality-Based Rehabilitation System; FDA Approval to Genesis’s Chocolate Touch® Drug-coated Balloon PTA Catheter; FDA Nod to AEYE’s AI-based Autonomous Screening; Alpheus Medical Treats First High-Grade Glioma Brain Cancer Patient with its Proprietary Platform; Karidum’s Next Generation Globe® Pulsed Field System

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US  On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...

Find More
Delveinsight
Genentech’s gantenerumab Fails in Phase III Trial; CHMP Recommends’ Dupixent; FDA Clears Imfinzi and Imjudo with chemotherapy; NICE Recommends Ipsen’s Cabometyx (cabozantinib); NICE Backs KEYTRUDA; NRG Announces £16 Million Series A Funding; FDA Backs AstraZeneca’s PT027

Genentech’s gantenerumab Fails in Phase III Trial for Alzheimer’s Disease In yet another setback for an amyloid-targeting drug, Roche's Genentech division has reported disappointing top-line results from its highly anticipated phase III trial of gantenerumab in early Alzheimer's disease. The failure is entirely ...

Find More
MedTech News for QuantuMDx, Medtronic, Exactech, and ProciseDx
QuantuMDx & Menarini’s Agreement; TruClear System Launched by Medtronic in India; FDA 510(k) Clearance for TriVerse Primary Knee Replacement System; FDA Clearance to ProciseDx’s Reactive Protein (CRP) Assay and ProciseDx Instrument; Evolution Optiks’s Enrollment of LFR-260 Phoropter in US; Kardium First-in-Human Clinical Study of the New Globe Pulsed Field System

QuantuMDx and Menarini Announced an Agreement for the Distribution of the Q-POCTM Platform On November 2, 2022, QuantuMDx Group Limited, a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), announced an exclusive distribution agreement for Qu...

Find More

The convergence of technologies and the increasing integration of medical devices to computer networ.....

Find More

Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification .....

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

A rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease wi.....

Find More

Cancer immunotherapy which is known to reactivate weakened immune cells of cancer patients, has yiel.....

Find More

Systemic Lupus Erythematosus (SLE) is an autoimmune disease where the immune system of the body mist.....

Find More